Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics innovator developing PCR-based testing solutions through its patented Co-Primers™ technology. This page serves as the definitive source for verified company news and announcements, providing stakeholders with timely updates on developments impacting global healthcare diagnostics.
Investors and industry professionals will find curated press releases covering financial results, regulatory milestones, product launches, and strategic partnerships. Our aggregation includes updates on CODX's expanding test menu (including tuberculosis and respiratory disease diagnostics), manufacturing expansions, and progress toward decentralized testing solutions through the Co-Dx™ platform.
Key resources include earnings call transcripts, FDA clearance announcements, and analysis of emerging market initiatives like the CoSara Diagnostics joint venture in India. All content is organized chronologically demonstrate the company's trajectory while maintaining compliance with financial disclosure standards.
Bookmark this page for direct access to primary source materials that inform investment decisions and industry analysis. Check regularly for updates on CODX's contributions to accessible, high-accuracy diagnostic testing worldwide.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its partner, Clinical Reference Laboratory, is offering an FDA-authorized Rapid Response COVID-19 Saliva Test through Walgreens Find Care. This non-invasive service allows consumers to undergo PCR-based COVID-19 testing at home using Co-Diagnostics' CoPrimer technology. The saliva samples are tested for SARS-CoV-2 via CRL's RT-PCR test. CEO Dwight Egan highlighted the importance of expanding accessibility to quality diagnostic solutions through at-home collection devices.
On February 24, 2021, Clinical Reference Laboratory (CRL) partnered with Walgreens to launch the FDA-authorized Rapid Response COVID-19 Saliva Test via Walgreens Find Care. This non-invasive test allows users to self-collect samples at home, boasting 100% sensitivity and specificity. Priced at $119, results are typically available within 24-48 hours. Walgreens aims to enhance access to COVID-19 testing, integrating it into their digital health platform. CRL has distributed over 500,000 tests, affirming its commitment to convenient and reliable testing solutions.
Co-Diagnostics, Inc. (Nasdaq: CODX) has appointed Brian Brown as Chief Financial Officer and Dr. Jesse Montgomery as Chief Scientific Officer, as part of its strategy for growth. Mr. Brown brings extensive financial experience, while Dr. Montgomery has previously served as Senior VP of Biochemistry. The company aims to enhance its financial department and scientific initiatives following significant growth and anticipates further progress in molecular diagnostics. Former CFO Reed Benson stays on as general counsel, and Dr. Brent Satterfield leads the Scientific Advisory Board.
Co-Diagnostics (Nasdaq: CODX) announced its participation in the 28th Annual International Molecular Medicine Tri-Conference, presenting its innovative Logix Smart SARS-CoV-2 DS (Direct Saliva) testing kit for COVID-19. The virtual presentation is scheduled for February 16, 2021, at 4:30 pm EST, including a test demonstration and a Q&A panel. The company aims to improve testing throughput and accessibility through this technology, which has been submitted for Emergency Use Authorization by the FDA. The test detects all known SARS-CoV-2 variants, enhancing global testing capabilities.
Co-Diagnostics (Nasdaq-CM: CODX) announced completion of its FDA submission for Emergency Use Authorization for its Logix Smart™ SARS-CoV-2 DS test, which detects COVID-19 in saliva samples without RNA extraction. This innovation aims to reduce testing costs and processing times, enhancing throughput in high-volume labs. CEO Dwight Egan emphasized the test's potential for quicker and affordable diagnostics, meeting rising global demand amidst the pandemic. The company continues to advance its proprietary technology to improve molecular diagnostics further.
Co-Diagnostics (Nasdaq-CM: CODX) will participate in the H.C. Wainwright & Co. BioConnect 2021 Conference from January 11-14, 2021. CEO Dwight Egan will join a panel hosted by former FDA Commissioner Scott Gottlieb on January 12 at 12:00 pm ET. Registration for the panel is available online. Additionally, Egan will engage in a fireside chat with Yi Chen, which will be accessible on-demand starting January 11 at 6:00 am ET through the Co-Diagnostics website.
The company specializes in molecular diagnostics, focusing on innovative tests for nucleic acid detection.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) anticipates reporting its highest quarterly revenue in history for Q4 2020, exceeding analyst estimates between $24 million and $25.98 million. This surge is attributed to increased demand for COVID-19 diagnostic products, showing a growth of 20-25% over Q3 2020 revenue of $21.82 million. CEO Dwight Egan highlighted the impact of COVID-19 in driving sales. However, final revenue figures may vary as they are based on preliminary internal financial reports, and readers are cautioned against reliance on forward-looking statements.
Co-Diagnostics, Inc. (Nasdaq: CODX) has completed the principal design for a PCR test targeting mutations in the new SARS-CoV-2 variant, VUI 202012/01. This strain exhibits several mutations and may be more transmissible. The company's CoPrimer platform is noted for its accuracy in distinguishing similar genetic sequences, reducing false positives. Co-Diagnostics emphasizes that the new test will be a distinct product and that existing COVID-19 diagnostics should remain unaffected. CEO Dwight Egan highlighted the rapid development capabilities of their technology.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced the sale of over 10 million Logix Smart™ COVID-19 Test Kits to laboratories and distributors worldwide. The company anticipates strong Q4 revenue exceeding Q3 2020 figures, highlighting the effectiveness of its business model. CEO Dwight Egan emphasized the company's commitment to providing high-quality diagnostics, including tests for influenza and multiplex tests in its portfolio. Additionally, Co-Diagnostics' joint venture in India received CDSCO clearance for various RT-PCR tests, expanding its reach in the diagnostics market.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its joint venture, CoSara Diagnostics Pvt Ltd, received clearance from India's Central Drugs Standard Control Organization to manufacture and sell the Saragene™ COVID-19 2-gene multiplex RT-PCR test. This in vitro diagnostic test targets the SARS-CoV-2 virus using patented CoPrimer™ technology and is designed to meet multi-target diagnostic needs. The test will support India's efforts to manage COVID-19 testing and aligns with World Health Organization guidelines.
